Abstract
Overview
Introduction
In 2007, more than 3 million new cases of solid tumors are forecast to be
diagnosed across the seven major pharmaceutical markets, obviously
representing an enormous market potential. Lower incidence tumor types are
becoming increasingly attractive to drug developers, due to high levels of
unmet need which can result in significant financial rewards.
Scope
- Examination of the solid cancer pipeline with in-depth clinical and
commercial profiles of Phase III candidates for 17 tumor types
- Seven major pharmaceutical sales forecasts for Phase III pipeline products
through to 2016 with product-specific assumptions
- Segmentation and analysis of the current solid tumor pipeline by
developmental phase, drug class and indication
- Insight and analysis of market potential including commercial opportunity,
epidemiology, commonalities across cancers and discussion of unmet needs
Report Highlights
The current solid tumor pipeline contains at least 707 unique agents, 9% of
which are in late-phase development. These products cover a vast array of
anticancer drug classes, including antihormonal therapies, cytotoxics, gene
therapies, immunotherapies, photodynamic therapies, radiotherapeutics,
targeted therapies and therapeutic vaccines.
The late-phase pipeline contains equal amounts of cytotoxics and targeted
therapies. The Phase I and II pipelines contain more than twice as many
targeted therapies as cytotoxics. As such, it is clear that increasing
diversity in terms of drug targets may result in greater treatment options in
years to come if positive clinical data is generated.
Despite high levels of unmet need and relatively healthy pipelines for most
indications, no major breakthroughs are expected by current late-phase
products aside from incremental increases in efficacy and reduced toxicity.
This indicates a heavy reliance on the earlier-phase pipeline for further
breakthroughs in terms of treatment of solid tumors.
Reasons to Purchase
- Identify key drugs and companies within the oncology pipeline based on
sales forecasts to 2016 and Datamonitor drug assessment
- Characterize unmet need and poorly served markets within oncology and
assess the potential for pipeline products to provide satisfaction
- Assess the shifting oncology market dynamic and how future treatment of
solid tumors will incorporate pipeline products
| 
View Cart
